UK – NICE publishes final guidance backing Jyseleca for rheumatoid arthritis

The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).

The FAD means that the daily oral pill will now be available on the NHS in England for the treatment of eligible adults patients with moderate-to-severe active RA.

To be eligible, patients with moderate-to-severe RA will have had an inadequate response to intensive therapy with two or more disease-modifying anti-rheumatic drugs (DMARDs).

Over 400,000 people in the UK live with RA – a degenerative auto-immune disease that can potentially cause life-threatening complications…